AR126891A2 - Vacunas de subunidades de rotavirus, métodos de preparación y uso de las mismas - Google Patents
Vacunas de subunidades de rotavirus, métodos de preparación y uso de las mismasInfo
- Publication number
- AR126891A2 AR126891A2 ARP220101959A ARP220101959A AR126891A2 AR 126891 A2 AR126891 A2 AR 126891A2 AR P220101959 A ARP220101959 A AR P220101959A AR P220101959 A ARP220101959 A AR P220101959A AR 126891 A2 AR126891 A2 AR 126891A2
- Authority
- AR
- Argentina
- Prior art keywords
- rotavirus
- animal
- polypeptides
- composition
- infected
- Prior art date
Links
- 241000702670 Rotavirus Species 0.000 title abstract 10
- 238000002360 preparation method Methods 0.000 title 1
- 229940031626 subunit vaccine Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 4
- 229960005486 vaccine Drugs 0.000 abstract 3
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 102100034343 Integrase Human genes 0.000 abstract 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract 1
- 241001506005 Rotavirus C Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Polipéptidos antigénicos o antígenos de rotavirus que provocan una respuesta inmune contra los rotavirus en un animal o en un ser humano. Composiciones que comprenden dichos polipéptidos de los rotavirus. Métodos de vacunación contra los rotavirus. Conjuntos de elementos que pueden usarse con dichos métodos y con dichas composiciones. Vectores de expresión novedosos para producir vacunas basadas en dichos polipéptidos antigénicos. Reivindicación 1: Una composición inmunológica caracterizada porque comprende a) uno o más polipéptidos que se seleccionan entre un polipéptido de un rotavirus o un fragmento de éste y b) un vehículo, un diluyente o un excipiente aceptable para aplicaciones farmacéuticas o veterinarias. Reivindicación 8: Un método para elaborar una composición autógena de acuerdo con cualquiera de las reivindicaciones 1 - 3, 5 ó 7, caracterizado porque comprende los siguientes pasos: (a) obtener una muestra biológica de un animal del que se sabe o se sospecha que está infectado por rotavirus de uno o más tipos; (b) si se desconoce el estado de la infección, determinar si el animal se encuentra infectado por rotavirus; (c) obtener ARN del animal que está infectado por los rotavirus de uno o más tipos; (d) poner en práctica una PCR mediante el uso de una transcriptasa inversa y de cebadores complementarios de al menos un gen de los rotavirus del grupo C; (e) insertar el producto de la PCR del paso (d) en un vector de expresión apropiado; (f) colocar el vector que se produjo en el paso (e) en un sistema hospedador apropiado para llevar a cabo la expresión; (g) obtener los polipéptidos de los rotavirus; y (h) agregar componentes adicionales para vacunas, de manera tal de obtener una composición que es útil como una vacuna. Reivindicación 12: Un método para vacunar un animal, caracterizado porque está basado en al menos una administración de una composición o un vector de acuerdo con cualquiera de las reivindicaciones 1 a 7.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261598624P | 2012-02-14 | 2012-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126891A2 true AR126891A2 (es) | 2023-11-29 |
Family
ID=47755047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100465A AR089995A1 (es) | 2012-02-14 | 2013-02-14 | Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas |
| ARP220101959A AR126891A2 (es) | 2012-02-14 | 2022-07-22 | Vacunas de subunidades de rotavirus, métodos de preparación y uso de las mismas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100465A AR089995A1 (es) | 2012-02-14 | 2013-02-14 | Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9446117B2 (es) |
| EP (1) | EP2814508B1 (es) |
| JP (1) | JP6149240B2 (es) |
| KR (1) | KR102087458B1 (es) |
| CN (1) | CN104203274B (es) |
| AR (2) | AR089995A1 (es) |
| AU (1) | AU2013221479B2 (es) |
| BR (1) | BR112014020025B1 (es) |
| CA (1) | CA2864106C (es) |
| DK (1) | DK2814508T5 (es) |
| EA (1) | EA034564B1 (es) |
| ES (1) | ES2632429T3 (es) |
| HK (1) | HK1200326A1 (es) |
| HU (1) | HUE033858T2 (es) |
| LT (1) | LT2814508T (es) |
| MX (1) | MX353786B (es) |
| NZ (1) | NZ628282A (es) |
| PH (1) | PH12014501795A1 (es) |
| PL (1) | PL2814508T3 (es) |
| PT (1) | PT2814508T (es) |
| SI (1) | SI2814508T1 (es) |
| WO (1) | WO2013123219A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10004797B2 (en) | 2010-10-27 | 2018-06-26 | Harrisvaccines, Inc. | Method of rapidly producing improved vaccines for animals |
| RU2649132C1 (ru) * | 2017-08-03 | 2018-03-29 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Способ получения активного начала вакцины против ротавирусной инфекции белка FliCVP6VP8 |
| CN108864260A (zh) * | 2018-07-17 | 2018-11-23 | 昆明学院 | 非结构蛋白nsp4、重组杆状病毒液及制备、粘膜佐剂 |
| CN109306007B (zh) * | 2018-09-26 | 2021-10-08 | 华中农业大学 | 抗猪繁殖与呼吸综合征病毒nsp4蛋白基因工程抗体及应用 |
| US20220160864A1 (en) * | 2020-10-05 | 2022-05-26 | Boehringer Ingelheim Animal Health USA Inc. | Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof |
| CN114875047A (zh) * | 2022-05-27 | 2022-08-09 | 江苏三仪生物工程有限公司 | 一种优化的猪轮状病毒外衣壳蛋白vp4的重组表达及应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| US5186933A (en) | 1986-12-30 | 1993-02-16 | Baylor College Of Medicine | Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system |
| US5147639A (en) * | 1990-06-19 | 1992-09-15 | Ambico, Inc. | Type-c rotavirus cultures and uses therefor |
| US5298244A (en) | 1990-10-25 | 1994-03-29 | University Of Saskatchewan | Assembled viral particles and their use in a vaccine to rotaviral disease |
| BE1006085A3 (fr) | 1992-07-31 | 1994-05-10 | Univ Bruxelles | Vecteur de clonage. |
| WO1996034109A1 (en) | 1995-04-25 | 1996-10-31 | Vical Incorporated | Single-vial formulations of dna/lipid complexes |
| US6673355B1 (en) | 1995-06-14 | 2004-01-06 | Baylor College Of Medicine | Rotavirus enterotoxin NSP4 and methods of using same |
| AU6387196A (en) * | 1995-06-14 | 1997-01-15 | Baylor College Of Medicine | Rotavirus enterotoxin nsp4 and methods of using same |
| US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
| FR2751226B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies du cheval |
| FR2751228B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Vaccin polynucleotidique bovin pour voie intradermique |
| FR2751227B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
| FR2751224B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs |
| FR2751229B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
| FR2751225B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
| WO1998016247A1 (en) | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| ATE275423T1 (de) | 1997-06-30 | 2004-09-15 | Aventis Pharma Sa | Verabreichung der nukleinsäure in den quergestreiften muskel |
| WO1999058652A2 (en) | 1998-05-07 | 1999-11-18 | Gx Biosystems A/S | Cytotoxin-based biological containment |
| FR2778858B1 (fr) | 1998-05-20 | 2000-06-16 | Oreal | Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique |
| US6716431B1 (en) | 1998-05-29 | 2004-04-06 | Wyeth Holdings Corporation | Differential cytotoxicity of alternative forms of rotavirus nonstructural protein 4 |
| US6187319B1 (en) | 1998-06-01 | 2001-02-13 | University Of Massachusetts | Cross-protective rotavirus vaccine |
| US6589529B1 (en) * | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
| FR2801607B1 (fr) | 1999-11-26 | 2001-12-28 | Merial Sas | Pneumovirus du canard et vaccins correspondants |
| US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
| US6867353B2 (en) | 2000-02-12 | 2005-03-15 | Exploregen Inc. | Production method of recombinant rotavirus structural proteins and vaccine composition |
| EP1349571A4 (en) * | 2000-11-03 | 2005-02-16 | Baylor College Medicine | ROTAVIRUS ENTEROTOXIN NSP4 AND METHOD FOR ITS USE |
| WO2004056390A1 (en) | 2002-12-19 | 2004-07-08 | Akzo Nobel Patent Department | Trivalent vaccine with maternal antibody transfer via the milk |
| DE602004013331T2 (de) | 2003-07-24 | 2009-07-16 | Merial Ltd. | Vakzin-formulierungen mit einer öl-in-wasser-emulsion |
| WO2006007555A2 (en) * | 2004-07-01 | 2006-01-19 | Children's Medical Center Corporation ¨ | Rotavirus antigens |
| US7691368B2 (en) * | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| BRPI0504441A (pt) | 2005-10-20 | 2007-06-26 | Fundacao Oswaldo Cruz | vetores de expressão plasmidial contendo regiões especìficas para a expressão de proteìnas ou epìtopos recombinantes de rotavìrus e astrovìrus, processo de produção dos insumos para geração de imunobiológicos para diagnóstico |
| KR20080100384A (ko) * | 2006-03-03 | 2008-11-17 | 메리얼 리미티드 | 마이코플라즈마 하이오뉴모니아에 백신 |
| US9169296B2 (en) | 2008-05-29 | 2015-10-27 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Expression and assembly of human group C rotavirus-like particles and uses thereof |
| EP2310511B1 (fr) | 2008-07-18 | 2015-01-14 | Sanofi Pasteur | Vecteur auto replicatif depourvu de gene de resistance a un antibiotique |
| MX2012002814A (es) | 2009-09-10 | 2012-08-17 | Merial Ltd | Nuevas formulaciones de vacuna que comprenden adyuvantes que contienen saponina. |
-
2013
- 2013-02-14 EP EP13706871.4A patent/EP2814508B1/en active Active
- 2013-02-14 NZ NZ628282A patent/NZ628282A/en unknown
- 2013-02-14 WO PCT/US2013/026179 patent/WO2013123219A1/en active Application Filing
- 2013-02-14 SI SI201330696T patent/SI2814508T1/sl unknown
- 2013-02-14 DK DK13706871.4T patent/DK2814508T5/da active
- 2013-02-14 US US13/767,569 patent/US9446117B2/en active Active
- 2013-02-14 BR BR112014020025-4A patent/BR112014020025B1/pt active IP Right Grant
- 2013-02-14 PL PL13706871T patent/PL2814508T3/pl unknown
- 2013-02-14 MX MX2014009722A patent/MX353786B/es active IP Right Grant
- 2013-02-14 JP JP2014557775A patent/JP6149240B2/ja active Active
- 2013-02-14 CA CA2864106A patent/CA2864106C/en active Active
- 2013-02-14 HU HUE13706871A patent/HUE033858T2/en unknown
- 2013-02-14 AU AU2013221479A patent/AU2013221479B2/en active Active
- 2013-02-14 CN CN201380015512.9A patent/CN104203274B/zh active Active
- 2013-02-14 PT PT137068714T patent/PT2814508T/pt unknown
- 2013-02-14 KR KR1020147025474A patent/KR102087458B1/ko active IP Right Grant
- 2013-02-14 ES ES13706871.4T patent/ES2632429T3/es active Active
- 2013-02-14 EA EA201400914A patent/EA034564B1/ru unknown
- 2013-02-14 LT LTEP13706871.4T patent/LT2814508T/lt unknown
- 2013-02-14 AR ARP130100465A patent/AR089995A1/es active IP Right Grant
-
2014
- 2014-08-08 PH PH12014501795A patent/PH12014501795A1/en unknown
-
2015
- 2015-01-23 HK HK15100745.1A patent/HK1200326A1/xx unknown
-
2022
- 2022-07-22 AR ARP220101959A patent/AR126891A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126891A2 (es) | Vacunas de subunidades de rotavirus, métodos de preparación y uso de las mismas | |
| Magini et al. | Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge | |
| Pillet et al. | Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets | |
| JP2017035093A5 (es) | ||
| CO2018005229A2 (es) | Vacuna de virus sincitial respiratorio | |
| Alberca et al. | Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge | |
| Verdecia et al. | COVID-19 vaccine platforms: Delivering on a promise? | |
| WO2016109792A3 (en) | Novel multivalent nanoparticle-based vaccines | |
| AR061152A1 (es) | Vacuna recombinante contra virus de la lengua azul | |
| TW200722101A (en) | Novel composition | |
| WO2015142671A3 (en) | Influenza virus vectors and uses therefor | |
| Calvo-Pinilla et al. | Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR (−/−) mice against lethal bluetongue infection | |
| SI2484375T1 (en) | A vaccine composition comprising a synthetic adjuvant | |
| JP2014534202A5 (es) | ||
| WO2016176624A3 (en) | Porcine pestvirus, vaccines, and assays | |
| EA201590597A1 (ru) | Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина | |
| EA201990718A1 (ru) | Векторы аденовируса собачьих | |
| EA201892735A1 (ru) | Состав вакцины против hiv | |
| McPherson et al. | Development of a SARS coronavirus vaccine from recombinant spike protein plus delta inulin adjuvant | |
| El Garch et al. | An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses | |
| FI3656395T3 (fi) | Menetelmiä ja koostumuksia suojaavan immuniteetin aikaansaamiseksi filovirusinfektiota vastaan | |
| Shen et al. | Development of a subunit vaccine containing recombinant chicken anemia virus VP1 and pigeon IFN-γ | |
| Gasmi et al. | A global survey in the developmental landscape of possible vaccination strategies for COVID-19 | |
| MX2015009507A (es) | Antigenos recombinantes del porcine circovirus 2 (pcv-2) para formulaciones de vacuna, kit de diagnostico y uso. | |
| PH12016502389A1 (en) | Antibody guided vaccines and methods of use for generation of rapid mature immune responses |